CONTENTS:
- Does the perception of risk associated with psychedelics use differ in physicians according to their belief of effectiveness? Bezo A., Roméo B., Le Strat Y., Strika-Bruneau L., Benyamina A., Hermand M., p. 1-6.
- Masking influences: A systematic review of placebo control and masking in psychedelic studies. Barstowe A., Kajonius P.J., p. 7-17.
- Global trends in psychedelic microdosing: Demographics, substance testing behavior, and patterns of use. Syed O.A., Petranker R., Fewster E.C., Sobolenko V., Beidas Z., Husain M.I., et al., p. 18-28.
- Aggression in a cohort of male methamphetamine (METH) users with and without kratom (Mitragyna speciosa Korth.) use history in Malaysia. Yang Y., Müller C.P., Singh D., p. 29-40.
- Kratom consumption - The tales of three patients. Gnanasegaram S.A., Sexton L., Stanciu C.N., p. 41-44.
- Safety and efficacy of Ashwagandha root extract on cognition, energy and mood problems in adults: Prospective, randomized, placebo-controlled study. Kale S., Lopresti A., Suri R., Garg N., Langade D., p. 45-57.
- Esketamine-induced dissociation: A case report. Scarcella J., MacDaniels J., Coffin L., Schwartz T., p. 58-62.
- Associations between ayahuasca use in naturalistic settings and mental health and wellbeing outcomes: Analysis of a large global dataset. Perkins D., Sarris J., Cowley-Court T., Aicher H., Tofoli L.F., Carlos Bouso J., et al., p. 63-74.
- Development, content validation and usability of a chatbot for disseminating scientific information about cannabis among young adults. Scherer J.N., de Oliveira G.R., Machado F.M.R., Gomes C.F., Ornell F., p. 75-84.
- The risk assessment before dose tapering among methadone maintenance treatment participants: Derivation and validation of a nomogram. Wang C., Lu Q., Li B., Tang X., Fan C., Ling L., p. 85-94.